Society of Hematologic Oncology Annual Meeting

In an interview with Consultant360, Junaid Anwar, MD, a hematology-oncology fellow at UT Health Houston, reviewed the current evidence base for JAK inhibitors in myelofibrosis from a pooled analysis of five...

Junaid Anwar, MD, discusses a meta-analysis of five landmark trials evaluating Janus kinase inhibitors for myelofibrosis, highlighting first-line efficacy and tolerability with ruxolitinib, second-line...

In a long-term follow-up to SIERRA, a multicenter, randomized, controlled phase 3 study, researchers found that patients 55 years of age or older with active relapsed or refractory acute myeloid leukemia...